Video

New Delivery Option for Ketamine

Author(s):

Jeffrey Becker, MD

How can new formulations of ketamine impact patient care?

Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.

Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
June 5th 2024

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

Mehdi Farokhnia, MD, MPH
Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.
May 30th 2024

Research and Opportunities at the 2024 ASCP Annual Meeting

Erin Crown, MHS, PA-C
Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.
May 30th 2024

Early Improvement of Symptoms in Bipolar 1 Depression

Anita H. Clayton, MD
Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.
May 30th 2024

Pseudospecific and Transdiagnostic Symptom Targeting in Clinical Trials

Joseph F. Goldberg, MD
Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!
May 29th 2024

Exciting Possibilities at ASCP 2024

Anita H. Clayton, MD
An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.
May 28th 2024

Navigating New Treatments for PTSD

Lori Davis, MD
© 2024 MJH Life Sciences

All rights reserved.